FINARO
11.3.2022 14:32:08 CET | Business Wire | Pressemeddelelse
Finaro (tidligere Credorax) , en global betalingsudbyder og Europæisk bank, der styrker international handel gennem teknologiske og enkle betalingsløsninger, har i dag offentliggjort, at de har indgået en aftale med Shift4 omkring salget af Finaro til en værdi af 575 millioner USD. Det kombinerede tilbud, fra begge virksomheder, skaber en positiv synergi af et globalt betalingsnetværk med en betydelig POS og eCommerce platform, på tværs af en bred vifte af vertikaler, der servicerer store og komplekse virksomheder med unikke løsninger. Sammen vil Finaro og Shift4 være bedre i stand til at forsyne virksomheder med globale betalingsløsninger gennem flere kanaler, og stå side om side med nogle af de største aktører i betalingsbranchen, heriblandt Adyen, Nuvei og WorldPay.
“Dette køb understreger vores offensive bestræbelser på, at levere en unified commerce oplevelse overalt i verden. Denne handel viser tydeligt vores evne til at støtte eksisterende transformerende og globale kunder, såsom SpaceX Starlink & St. Jude Children’s Research Hospital,” fortæller Shift4s CEO Jared Isaacman.
Finaro vil levere den globale infrastruktur og den nødvendige banebrydende teknologi, for at føre Shift4s internationale ambitioner ud i livet om at levere en unified commerce løsning. Ved at integrere Finaros kapaciteter, vil Shift4 være i stand til at udvide virksomhedens nuværende serviceydelser overalt i verden, inklusiv dens næste generation af SkyTab POS-løsning, Shift4Shop e-handelsplatform og VenueNext stadiontilbud. Shift4 har også mere end 425 softwareintegrationer og over 200.000 merchants, hvoraf mange har en multinational tilstedeværelse, og giver øjeblikkelige internationale muligheder, som der nu kan åbnes for som et resultat af denne nyerhvervelse.
“Denne erhvervelse understreger, at vi har opnået, hvad vi har sat os for at opnå – at opbygge pålidelige betalingsbehandlingskapaciteter, som i sandhed er uden grænser, både hvad angår tilgængelighed og størrelse. At kunne anvende denne teknologi til SpaceXs Starlink-program, og andre der er tilsvarende i størrelsen, samtidig med også at kunne tilbyde vores virksomheder og partnere overalt i verden et bredere udvalg af produkter og serviceydelser, er realiseringen af dette mål på den mest konkrete måde, og vi er begejstrede over at blive en del af Shift 4- teamet,” fortæller Igal Rotem, CEO for Finaro.
For yderligere information om denne nyerhvervelse, besøg venligst præsentationssektionen på Shift4s Investor Relations website her .
###
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220311005243/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum